Efficacy, safety and tolerability of CRB-913 in the phase 1b CANYON-1 study
Scientific Posters , CRB-913 , 1b CANYON-1 study

Efficacy, safety and tolerability of CRB-913 in the phase 1b CANYON-1 study

20 November 2026
Overview

The cannabinoid receptor type 1 (CB1) is a G protein-coupled receptor with a well-established role in obesity and metabolism, 
and is abundant in the brain and in peripheral metabolic organs including the liver, pancreas, muscles and adipose tissue. This 
insight led to the development of the first-generation CB1 inverse agonists for the treatment of obesity two decades ago.

Download the "Efficacy, safety and tolerability of CRB-913 in the phase 1b CANYON-1 study" poster.

Download
Date
20 November 2026

Translational Pharmaceutics® for integrated drug development

We can apply Translational Pharmaceutics® to your next drug program, whether your goal is getting to first-in-human trials faster, optimizing your drug product further coming out of Phase I studies, or for enabling more successful human ADME programs.

Image
How does Translational Pharmaceutics work?

Learn more about Translational Pharmaceutics®:

Latest News
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline By: Dr. Andrew Lewis
Read More
News & Announcements, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences shortlisted for "Best Use of AI in Clinical Development & Trial Innovation" at the Scrip Awards 2026 By: Dr. Andrew Lewis
Read More
News & Announcements, Nottingham, UK, Artificial Intelligence, Translational Pharmaceutics®, Formulation Development Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation in Clinical Study By: Dr. Andrew Lewis
Read More
Let's Talk
Where integrated CRDMO services bring therapies to life. Start a conversation today.